申请人:Neurogen Corporation
公开号:US20020019406A1
公开(公告)日:2002-02-14
Disclosed are compounds of the formula:
1
wherein Ar, R
1
, R
2
, R
3
, R
4
and R
5
are defined herein, which compounds are selective antagonists at CRF1 receptors and are therefore useful in the diagnosis and treatment of stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache, anxiety, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also disclosed.
本发明公开了以下式子的化合物
1
其中 Ar、R
1
, R
2
, R
3
, R
4
和 R
5
在此定义,这些化合物是 CRF1 受体的选择性拮抗剂,因此可用于诊断和治疗与应激有关的疾病,如创伤后应激障碍 (PTSD),以及抑郁症、头痛、焦虑症、心血管疾病和饮食失调。此外,还公开了治疗此类疾病的方法以及包装药物组合物。